000			05390nam a22004693i 4500
001			EBC4877812
003			MiAaPQ
005			20240729131304.0
006			m o d |
007			cr cnu||||||||
008			240724s2017 xx o ||||0 eng d
020			_a9781681081878 _q(electronic bk.)
020			_z9781681081885
035			_a(MiAaPQ)EBC4877812
035			_a(Au-PeEL)EBL4877812
035			_a(CaPaEBR)ebr11398513
035			_a(OCoLC)990408952
040			_aMiAaPQ _beng _erda _epn _cMiAaPQ _dMiAaPQ
050		4	_aRC628.A585 2017
082	0		_a616.39800000000002
100	1		_aRahman, Atta-ur.
245	1	0	_aAnti-Obesity Drug Discovery and Development Volume 3.
250			_a1st ed.
264		1	_aSharjah : _bBentham Science Publishers, _c2017.
264		4	_c©2017.
300			_a1 online resource (245 pages)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
490	1		_aAnti-Obesity Drug Discovery and Development ; _vv.3
505	0		_aIntro -- CONTENTS -- PREFACE -- List of Contributors -- Current Status of Medical Therapy and New Targets for Anti-Obesity Drug Development -- Chihiro Okuma, Yukihito Ishii and Takeshi Ohta* -- INTRODUCTION -- Approved Drugs -- Phentermine -- Mazindol -- Fenfluramine/Dexfenfluramine -- Orlistat -- Shibutramine -- Rimonabant -- Qsymia -- BELVIQ (Lorcaserin) -- Contrave -- New Drug Targets (Table 3) -- Late Phase Clinical Development -- Early Phase Clinical Stage Development or Pre-Clinical Development Stage Late Phase Clinical Development -- Future Prospects -- Obesity Animal Models -- ob/ob Mouse -- db/db Mouse -- KK-Ay Mouse -- TSOD Mouse -- SDT fatty Rat -- ZF Rat -- ZDF Rat -- cp/cp Rat -- WBN/Kob fatty Rat -- DIO Models -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Unravelling Potential Anorexigen Effects of Nesfatin-1: How Homeostatic Mechanisms Help Balance Excess Calories -- Carmine Finelli* -- INTRODUCTION -- Nesfatin-1/NUCB-2 and Anorexigenic Effect -- The Oxytocin Pathway in Nesfatin-1's Inhibitory Effect on Food Intake -- Nesfatin-1 and CRF -- Nesfatin-1 and Anti-Obesity Treatment -- Nesfatin-1 and Food Behaviour Control -- Nesfatin-1 and Signaling Pathway -- Nesfatin-1 and Eating Disorders -- CONCLUSIVE REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Proteomics in the Characterization of New Target Therapies in Pediatric Obesity Treatment -- Gillian E. Walker1,*, Marilisa De Feudis1, Marta Roccio1, Gianni Bona2 and Flavia Prodam2 -- INTRODUCTION -- CHILDHOOD OBESITY: PATHOLOGICAL BASIS -- Genetic Considerations for Childhood Obesity -- Energy Homeostasis Dysregulation -- Pathophysiology of Adipose Tissue -- PROTEOMICS -- Gel Based Methods -- Non Gel Based Methods: Mass Spectrometry (MS) -- Chips -- Challenges -- PROTEOMIC STUDIES OF ADIPOSE TISSUE -- WAT Depots -- WAT Secretome.
505	8		_aBAT -- Stromal-Vascular Fraction (SVF) -- PROTEOMIC STUDIES IN ADIPOCYTES: STEM CELLS AND CELL LINES -- Adipogenesis: Adipo-proteomics -- Murine 3T3-L1 Preadipocytes -- Adipocyte-Derived Stem Cells (ASCs) -- Adipocyte Secretome -- Post-Translational Modifications (PTMs) -- PROTEOMIC PROFILING: TISSUES AND CIRCULATION -- Fetal Programming: Tissue-Specific Biomarkers -- Circulating Biomarkers -- Urine Biomarkers -- OUTLOOKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Relationship Between Hormonal Milieu and Oxidative Stress in Childhood Obesity: A Physiopathological Basis for Antioxidant Treatment and Prevention of Cardiovascular Risk -- Antonio Mancini*, Francesco Leo, Chantal Di Segni, Sebastiano Raimondo and Aurora Natalia Rossodivita -- INTRODUCTION -- OBESITY AND OXIDATIVE STRESS -- Hormones and Inflammatory Molecules Produced by or Related to Adipose Tissue -- Oxidative Stress in Childhood Obesity -- HORMONAL REGULATION OF ANTIOXIDANT SYSTEMS AND THEIR DERANGEMENT IN CHILDHOOD OBESITY -- Growth Hormone (GH) -- Thyroid -- Adrenal Glands -- Gonads -- Adipose tissue (Leptin and Kisspeptin) -- ANTIOXIDANT-ENRICHED DIET AS A TREATMENT FOR OBESITY -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Role of Gut Microflora in Obesity - Does the Data Provide an Option for Intervention? -- Parth J. Parekh1, Edward C. Oldfield, IV2, Amrit Lamba3 and David A. Johnson4,* -- INTRODUCTION -- OBESITY AND THE MICROFLORA: A BRIEF OVERVIEW -- DATA AND OPTIONS FOR INTERVENTION -- Antibiotics -- Probiotics -- Prebiotics -- Synbiotics -- The Role of Fecal Transplant -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- SUBJECT INDEX.
588			_aDescription based on publisher supplied metadata and other sources.
590			_aElectronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
650		0	_aObesity.
655		4	_aElectronic books.
700	1		_aChoudhary, M. Iqbal.
776	0	8	_iPrint version: _aRahman, Atta-ur _tAnti-Obesity Drug Discovery and Development Volume 3 _dSharjah : Bentham Science Publishers,c2017 _z9781681081885
797	2		_aProQuest (Firm)
830		0	_aAnti-Obesity Drug Discovery and Development
856	4	0	_uhttps://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4877812 _zClick to View
999			_c127174 _d127174